Skip to content
by Legal Desire
28 April 2022

Latham & Watkins Advises Zentalis Pharmaceuticals on US$25 Million Equity Investment from Pfizer

Advising firms

Deal team

12 lawyers named
LawyerFirmSeniorityPracticeOffice
Nathan Ajiashvili Lead Latham & Watkins LLP Partner corporate New York
Salvatore Vanchieri Latham & Watkins LLP Associate corporate New York
Matt DeSilva Latham & Watkins LLP Associate corporate New York
Darby Dietrich Latham & Watkins LLP Associate corporate New York
Darryl Steensma Latham & Watkins LLP Counsel collaboration matters San Diego
Pardis Zomorodi Latham & Watkins LLP Partner tax matters Los Angeles
Sam Weiner Latham & Watkins LLP Partner tax matters Century City
Ryan Brenner Latham & Watkins LLP Associate tax matters Century City
Heather Deixler Latham & Watkins LLP Partner data privacy & security matters Bay Area
Fiona Maclean Latham & Watkins LLP Partner data privacy & security matters London
Oliver Mobasser Latham & Watkins LLP Associate data privacy & security matters London
Lorenzo Meusburger Latham & Watkins LLP Associate data privacy & security matters London

Stated terms

Stated value
USD 25m (US$25 million)
What the figure measures
Issue size
Client
Zentalis Pharmaceuticals, Inc.Issuer
Counterparties
Pfizer (Investor)